Facts and Figures

Full project title:PRISM - Psychiatric Ratings using Intermediate Stratified Markers
Start date:1 April 2016
Duration:Phase 1 - 3 years (2016 – 2019)
Phase 2 - 2 years (2019 – 2021)
Estimated costs:€ 16.5 million
Project coordinator:University of Groningen, Netherlands
Prof Dr Martien Kas
Project leader:Eli Lilly and Company Ltd
Dr Hugh Marston
Funding:Innovative Medicines Initiative 2 Joint Undertaking:
European Union’s Horizon 2020 research and innovation programme and EFPIA

Innovative Medicine Initiative (IMI) is Europe’s largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.

Read more